araag2/HINT huggingface dataset:
Clinical trial NCT00714649 (phase 1/phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  More than 18 years

          -  Histologically proven squamous cell carcinoma of the oral cavity, oropharynx,
             hypopharynx or larynx

          -  patients selected for a primary surgical treatment

          -  No distant metastases

          -  No active second malignancy during the last 5 years

          -  No prior or concurrent evidence of uncontrolled severe pathology precluding
             administration of surgery

          -  life expectancy more than 3 months

          -  Not pregnant or nursing; fertile patients both male or female, must use effective
             contraception

          -  Signed informed consent

          -  Performance Status ECOG 0-1

        Exclusion Criteria:

          -  Nasopharynx cancer

          -  Past or current malignancy other than HNSCC

          -  performance Status ECOG above 2

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Use of any investigationals agents within 4 weeks prior ti entry

          -  Previous exposure to EGFR targeting therapy

          -  Known grade hypersensitivity to cetuximab
Clinical trial NCT01218477 (phase 1/phase 2, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dasatinib, bms-833923
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Key Inclusion Criteria

          -  Age ≥18 years

          -  Diagnosis of chronic myeloid leukemia (CML) and cytogenetic positive for the
             Philadelphia chromosome (Ph+), documented Ph+ cells on bone marrow assessment (BMA) ≤6
             weeks prior to treatment

          -  Either chronic-phase CML, with <15% blasts in peripheral blood and bone marrow, or
             advanced-phase CML, including Ph+ acute lymphoblastic leukemia (ALL) (> 5% blasts) or
             hematologic progression with ≥15% blasts not in complete cytogenetic remission

          -  Resistance or suboptimal response to imatinib, dasatinib, or nilotinib and no known
             T315I/A Abl-kinase mutation.

        Key Exclusion Criteria

          -  Known Abl-kinase T315I or T315A mutation

          -  CCyR at baseline

          -  Any serious or uncontrolled medical disorder or active infection that would impair the
             ability of the subject to receive protocol therapy

          -  Uncontrolled or significant cardiovascular disease

          -  Grade 3 or higher peripheral blood counts

          -  Serum calcium or phosphate below the lower limit of normal

          -  Baseline hypomagnesemia and amylase or lipase at least Grade 1 or higher

          -  Reduced renal function, defined as serum creatinine level >3*upper limit of normal

          -  Prior therapies for CML or Ph+ ALL permitted, with the following restriction:

               -  Therapy permitted with corticosteroids, hydroxyurea, or anagrelide prior to
                  starting treatment and during the first 4 weeks on study

               -  6 months or longer after stem cell transplantation

               -  28 days or longer after any investigational agent

               -  7 days or longer after any standard chemotherapy agent

               -  Concomitant use of medications with a known risk of causing Torsades de Pointes

               -  Concomitant use of strong inhibitors of the CYP3A4 isoenzyme
Clinical trial NCT00100971 (phase 1, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: autologous tumor cell vaccine, therapeutic autologous dendritic cells
SMILES: [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O
Reason stopped: 
    protocol is withdrawn due to inadequate accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia (AML) by bone marrow biopsy

               -  Newly diagnosed

          -  Must have adequate dendritic cells and AML blasts isolated from bone marrow and/or
             peripheral blood

          -  No clinical evidence of CNS leukemia

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No clinically significant autoimmune disease

          -  No other active malignancy except nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 3 months since prior immunotherapy

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT00640315 (phase 1, status: completed)
Conditions: hypertension, pulmonary, pulmonary disease, chronic obstructive
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22, J44.9, J44.1, J44.0
Drugs: riociguat (adempas, bay63-2521) 1.0 mg, riociguat (adempas, bay63-2521) 2.5 mg
SMILES: COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with pulmonary hypertension due to COPD, undergoing routine invasive
             measurement of hemodynamic parameters.

          -  Catheters for measurement of hemodynamic parameters (PAP [pulmonary artery pressure],
             PCWP [pulmonary capillary wedge pressure], CO [cardiac output], SBP [systolic blood
             pressure]) must be in place independent of the trial.

        Exclusion Criteria:

          -  Acute exacerbation of COPD,

          -  Pre-existing lung disease other than COPD,

          -  Acute or severe chronic left heart failure,

          -  Severe coronary artery disease,

          -  Uncontrolled arterial hypertension;

          -  Severe left ventricular hypertrophy,

          -  Congenital or acquired valvular or myocardial disease,

          -  Systolic blood pressure < 100 mmHg,

          -  Heart rate < 55 bpm or >105 bpm,

          -  PaO2 (arterial partial oxygen pressure)/FiO2 (fraction of inspired oxygen) < 50 mmHg,

          -  PaCO2 (arterial partial pressure of carbon dioxide) > 55 mmHg,

          -  Severe hepatic insufficiency,

          -  Severe renal insufficiency.
Clinical trial NCT00444236 (phase 1, status: terminated)
Conditions: exercise triggered asthma, gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: nexium, placebo
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the sponsor decided to terminate the study due to slow enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  We plan to take athletes (cyclists) with GER (heartburn symptoms on a daily-weekly
             basis which are either improved by a trial of acid suppression or objectively
             documented via pH/endoscopic testing- this may include during exercise) who experience
             one or more of the following symptoms during exercise, limiting their perceived
             ability to exercise to full capacity:

               -  choking

               -  cough

               -  wheezing

               -  shortness of breath

               -  chest tightness during exercise

          -  Athletes will be defined as persons who exercise on a routine basis (at least 3 times
             a week on average) for at least the past 6 months.

          -  Subjects must be at least 18 years old.

        Exclusion Criteria:

          -  Pregnancy

          -  Age less than 18 years or greater than 65 years

          -  Abnormal methacholine challenge tests will not exclude one from enrollment as (has
             been documented in a prior study) often patients with GER will have heightened
             bronchial reactivity.
Clinical trial NCT00591214 (phase 1, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: mp-424 (telaprevir)
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with genotype 1b chronic hepatitis C

          -  Patients naive to the concomitant medications with interferon

        Exclusion Criteria:

          -  Patients diagnosed with decompensated cirrhosis

          -  Patients diagnosed with positive HBs(Hepatitis B virus surface) antigen in the test
Clinical trial NCT00088023 (phase 1, status: terminated)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pt-523 for injection
SMILES: NC1=NC(N)=C2N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCCNC(=O)C3=CC=CC=C3C(O)=O)C(O)=O)C=NC2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Presence of metastatic or inoperable malignancy, other than leukemia or a primary
             central nervous system (CNS) tumor, for which there is no known curative or survival
             prolonging palliative therapy, or failure of these therapies .

          -  Age greater than or equal to 18 years.

          -  Life expectancy greater than or equal to 2 months.

          -  ECOG performance status 0 - 2.

          -  Adequate organ function and bone marrow reserve.

          -  Use of appropriate contraceptive method.

          -  Sign patient informed consent.

        Exclusion Criteria:

          -  Active brain metastases.

          -  Presence of third-space fluid collections (pleural effusion, ascites).

          -  Major surgery within 3 weeks prior to dosing.

          -  Prior chemotherapy or radiation therapy within 3 weeks prior to dosing (6 weeks for
             nitrosoureas or mitomycin-C). Prior antifolate therapy is permitted, as long as it has
             not been administered within 3 weeks prior to dosing with PT-523.

          -  Prior bone marrow transplantation.

          -  Presence of uncontrolled serious medical or psychiatric illness.

          -  Patients requiring radiation therapy.

        There are no limitations on the extent or type of prior therapy received by the patient
        other than the time intervals indicated above, as long as the patient has demonstrated
        complete recovery from any adverse effects, and fulfills all relevant inclusion criteria.
Clinical trial NCT01166789 (phase 1, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: lubiprostone, placebo
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  clinical diagnosis of IBS-C

          -  meeting Rome III diagnostic criteria for IBS-C

          -  age 18 or older

        Exclusion Criteria:

          -  use of laxatives or prokinetics within two weeks prior to the study or during the
             study

          -  use of IBS-specific compounds, opiates, anticholinergics, or any drug likely to cause
             constipation as a side-effect

          -  use of analgesics for 48 hours prior to the study

          -  hypothyroid condition

          -  history of bowel resection except appendectomy or cholecystectomy

          -  psychotic disorder, major depression, substance abuse (other than tobacco), or other
             psychiatric condition likely to interfere with the conduct of the study. Subjects
             treated for depression more than 2 years ago or for situational circumstances may be
             eligible for the study at the investigator's discretion

          -  renal disease

          -  inflammatory or ischemic disease of the rectum

          -  known to be an unreliable subject

          -  Because this study involves exposure to radiation, subjects who are pregnant or
             planning to become pregnant, employees currently working with radiation, and subjects
             who have participated in research involving radiation within the past year will also
             be excluded.
Clinical trial NCT00291577 (phase 1, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sunitinib (sutent), taxotere
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Breast cancer with evidence of unresectable, locally recurrent or metastatic disease

          -  Candidate for treatment with docetaxel

        Exclusion Criteria:

          -  Prior chemotherapy in the advanced disease setting

          -  Inflammatory breast cancer

          -  HER2 positive disease
Clinical trial NCT00087477 (phase 1/phase 2, status: terminated)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: pivanex
SMILES: CCCC(=O)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed melanoma, previously treated with
             chemotherapy or IL-2

          -  Recurrent or progressive disease after treatment.

          -  Measurable disease.

          -  Males and females, age ≥ 18 years.

          -  Adequate renal function with creatinine ≥ 1.5 mg/dl.

          -  Adequate liver function with alkaline phosphatase <= 2.5 X upper limit of normal, SGOT
             and SGPT <= 1.5 X upper limit of normal and total bilirubin <= 1.5 X upper limit of
             normal.

          -  Adequate bone marrow function: platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, and
             absolute neutrophil count (ANC)≥ 1,500 cells/mm3.

          -  Able to give informed consent.

          -  Must have discontinued previous surgery, radiation therapy or cancer chemotherapy at
             least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin
             C), with recovery from treatment-associated toxicity. Localized palliative radiation
             therapy to non-target lesions is permitted within the four weeks prior to
             randomization.

          -  A predicted life expectancy of at least 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Exclusion Criteria:

          -  Receipt of more than three (3) systemic treatment regimens for malignant melanoma
             (including IL-2).

          -  A second malignancy within the last 5 years other than curatively treated
             carcinoma-in-situ or non-melanoma skin cancer.

          -  Pregnant or lactating females. Females of childbearing potential must have a negative
             pregnancy test and all male and female patients of reproductive potential must agree
             to use adequate birth control.

          -  Known HIV-positive patients.

          -  Acute medical problems, such as ischemic heart or lung disease or uncontrolled
             systemic infection.

          -  Patients with any underlying medical conditions or circumstance, which would
             contraindicate therapy with study treatment, affect compliance or impair evaluation of
             study endpoints.

          -  Patients receiving investigational agents within 4 weeks of randomization.

          -  Known allergy to reagents in the study.

          -  Symptomatic or untreated brain metastases - Patients with brain metastases are
             eligible if they are clinically and neurologically stable for ≥ 4 weeks since therapy
             (radiation therapy, radiosurgery/gamma knife, surgical resection) as determined by the
             investigator and either off corticosteroids or on a stable dose of corticosteroids.
Clinical trial NCT00327327 (phase 1, status: completed)
Conditions: pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: imexon, gemcitabine
SMILES: NC1=NC(=O)N2CC12, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Inoperable cancer of the pancreas.

          -  Blood cell counts and blood chemistries in or near normal range.

          -  Able to perform the activities of daily living.

          -  A projected life expectancy of at least 2 months.

          -  If female, neither pregnant nor nursing.

          -  Willing to use contraceptives to prevent pregnancy.

          -  No other serious illnesses.

          -  No other active malignancy.

          -  No serious infections.

          -  No current other drug therapy for the cancer or steroid therapy.

          -  Prior radiation is permitted as is chemotherapy given during radiation or to prevent
             relapse after surgical removal of the disease.

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic disease.

          -  Brain metastases
Clinical trial NCT00473616 (phase 1, status: terminated)
Conditions: advanced solid tumors, cancer, advanced solid malignancies
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd7762, irinotecan
SMILES: [H][C@@]1(CCCNC1)NC(=O)C1=C(NC(O)=N)C=C(S1)C1=CC(F)=CC=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    termination of the study was made after a full review of program data and assessment of the
    current risk-benefit profile.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced solid tumors for which standard treatment doesn't exist or is no longer
             effective.

          -  Must be suitable for treatment with irinotecan

          -  Relatively good overall health other than your cancer

        Exclusion Criteria:

          -  Poor bone marrow function (not producing enough blood cells)

          -  Serious heart conditions

          -  Poor liver or kidney function

          -  Any prior anthracycline treatment
Clinical trial NCT00163098 (phase 1/phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: uk-369,003
SMILES: CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  GOLD criteria 2 to 4

          -  10 pack year history of smoking

        Exclusion Criteria:

          -  Women of child bearing potential
Clinical trial NCT02211872 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bi 2536 bs, intravenous
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with confirmed diagnosis of advanced, non resectable and / or metastatic
             solid tumours, who had failed conventional treatment, or for whom no therapy of proven
             efficacy exists, or who were not amenable to established forms of treatment

          -  Evaluable tumour deposits

          -  Age of 18 years or older

          -  Life expectancy of at least 6 months

          -  Written informed consent consistent with international conference of harmonization
             (ICH) - good clinical practice (GCP) and local legislation

          -  Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ≤ 2

          -  And full recovery from all therapy-related toxicities from previous chemo-, hormone-,
             immuno-, or radiotherapies

        Exclusion Criteria:

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the trial protocol

          -  Pregnancy or breastfeeding

          -  Active infectious disease

          -  Known brain metastases

          -  Second malignancy requiring therapy

          -  Absolute neutrophil count less than 1500/mm3

          -  Platelet count less than 100 000/mm3

          -  Bilirubin greater than 1.5 mg/dL (> 26 μmol/L, international system of units (SI)
             equivalent)

          -  Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than 2.5 times the upper limit of normal (if related to liver metastases greater than
             five times the upper limit of normal)

          -  Serum creatinine greater than 1.5 mg/dL (> 132 μmol/L, SI unit equivalent)

          -  Sexually active women and men who are unwilling to use a medically acceptable method
             of contraception

          -  Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

          -  Chemo-, radio or immunotherapy within the past four weeks before start of therapy or
             concomitantly with this trial

          -  Patients unable to comply with the trial protocol

          -  Or active alcohol or drug abuse